Rilvegostomig trials for Non-Small-Cell Lung Cancer

All Rilvegostomig trials · All Non-Small-Cell Lung Cancer trials

Phase breakdown

Recruiting trials studying Rilvegostomig for Non-Small-Cell Lung Cancer

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 325 locations
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 83 locations
• A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
  NCT07115043 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 26 locations
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
  NCT05061550 · Phase: Phase 2 · Ages: 18 Years to 95 Years · Sex: All (male and female) · 97 locations
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 287 locations

Common questions

How many trials study Rilvegostomig for Non-Small-Cell Lung Cancer?

5 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.